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therapeutic option or solution?
ABSTRACT
Atrial fibrillation (AF) is the most common type of arrhythmia. AF increases the risk of thromboembolic 
complications including stroke. Stroke in patients with AF is more severe compared with patients with 
sinus rhythm. Long-term oral anticoagulant therapy (OAT) is widely used in a large population of patients 
with AF to prevent arterial thromboembolic events, such as stroke and systemic embolism. However, it is 
well established that OAT significantly increases the risk of bleeding. Percutaneous left atrial appendage 
closure (LAAC) is an option for stroke prophylaxis in patients with nonvalvular AF and high risk of bleeding. 
This paper provides an overview of recent studies that address the effectiveness and safety of LAAC using 
the Amplatzer Cardiac Plaque and Watchman Left Atrial Appendage System. LAAC provides a superior 
choice of treatment in patients with absolute contraindication of systemic OAT, in cases of refusal of 
systemic OAT by a patient, and as a complementary treatment to anticoagulation in patients with embolic 
events despite adequate OAT. LAAC should be also considered as a therapeutic option for patients with 
high thromboembolic risk and very high bleeding risk on the basis of individual risk/benefit evaluation 
for OAT vs. alternative methods of treatment. In general, LAAC becomes more attractive with increasing 
thromboembolic risk. There is a need for further studies to address the question of whether LAAC is ac-
tually the best method for preventing thromboembolism for patients with moderate/high thromboembolic 
risk and relatively low bleeding risk, to determine the optimum antithrombotic or antiplatelet therapy in 
patients who underwent LAAC, as well as to conduct direct comparative analysis of LAAC and the use of 
new oral anticoagulant drugs (NOAC).
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Introduction
Atrial fibrillation (AF) is the most common type of 
arrhythmias, it affects about 2% to 3% of the European 
population and both: United States and Canada [1, 2]. 
Management of patients with AF is a common but 
still difficult clinical problem. AF increases the risk of 
thromboembolic complications, including stroke (pa-
tients with AF are almost five times more likely to have 
stroke compared with patients with sinus rhythm) [1, 2]. 
Moreover, the stroke in patients with AF is more severe. 
Long-term oral anticoagulant therapy (OAT) is 
widely used in a large population of patients with AF to 
prevent arterial thromboembolic events, such as stroke 
and systemic embolism. Health care professionals in 
their everyday practice face a dilemma, while it is well 
established that OAT increases the risk of bleeding 
[3–7]. Because of that, this therapy is the most common, 
but not the safest or most effective for each patient. 
Currently physicians along with well-informed patients 
may choose one of several options for stroke prophylax-
is. Until recently vitamin K antagonists (VKAs) were the 
only therapeutic option and have been recommended 
for thromboembolic prophylaxis in the group of high 
risk patients with AF [8, 9]. 
However, the use of VKAs is limited by an increased 
risk of bleeding (which results in high rates of drug 
discontinuation), narrow therapeutic range and diet 
interactions. Because of bleeding complications about 
40% of patients qualified to warfarin do not receive 
therapy of proven efficacy [10, 11]. These patients were 
very often treated just with aspirin [12, 13]. 
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Health care professionals have observed a turning 
point in the clinical development of new oral antico-
agulant drugs (NOACs), currently known as drug an-
ticoagulant non-vitamin K antagonists (DAnonVKAs), 
during the past decade [14]. The DAnonVKAs include: 
direct thrombin inhibitors (e.g dabigatran) and factor 
Xa inhibitors (e.g rivaroxaban, apixaban). Further-
more, multi-centre randomised controlled trials (RCT) 
demonstrated that DAnonVKAs are non-inferior or even 
superior compared with warfarin in both stroke and 
systemic embolism prevention, with reduced bleeding 
rates [11, 15–18]. Currently DAnonVKAs are used as 
a complementary therapy, but certainly in the future 
they will replace VKAs and heparins in the treatment 
and prevention of arterial as well as venous thromboem-
bolism [14]. However, we all know that anticoagulation 
with VKAs as well as DAnonVKAs is associated with 
bleeding complications [3–7]. Nowadays there is an 
alternative strategy. Percutaneous left atrial appendage 
closure (LAAC) is the third option of stroke prophylaxis 
in patients with nonvalvular AF. The idea is based on 
the finding, further improved by autopsy and echocar-
diographic studies, that in patients with nonvalvular 
AF about 90% of thrombi are localised in the left atrial 
appendage (LAA) [19]. 
There are two the most popular systems used to 
close LAA: the Watchman LAAC system (Boston Scien-
tific Corporation, Saint Paul, Minnesota), and Amplatzer 
Cardiac Plug (ACP) (St. Jude Medical, Minneapolis, 
Minnesota) including its second generation Amulet 
(Figs. 1–4) [20–23]. The European Society of Cardiology 
(ESC) implemented a class II B recommendation for 
LAAC for patients with nonvalvular AF, who are either 
contraindicated or unsuitable for long-term OAT-owing 
Figure 2. Watchman™ Left Atrial Appendage Closure Device 
(adapted from the official website of Boston Scientific) [65]
Figure 1. Watchman™ Left Atrial Appendage Closure Device 
(adapted from the official website of Boston Scientific) [65]
to high bleeding risk (HAS-BLED score equal to 3 or 
more), or as an alternative treatment [24–27]. According 
to the European Heart Rhythm Association (EHRA) and 
European Association of Percutaneous Cardiovascular 
Interventions (EAPCI), LAAC is recommended in pa-
tients with AF and indication for OAT for stroke/embo-
lism prevention (with CHA2DS2-VASc score > 1 point) 
and: increased risk of bleeding (HAS-BLED score 
3 points or more), contraindications for OAT, or refusal 
of treatment with OAT [1].
Left atrial appendage closure 
procedure
Before the procedure all patients should undergo 
transoesophageal echocardiography (TEE) to assess 
the anatomical type of this structure and to rule out 
thrombus inside LAA [1, 23]. In most cases the device 
implantation is performed under general anaesthesia 
with TEE and fluoroscopic guidance [1, 23]. Before the 
procedure patients are given a loading dose of aspirin 
(325 mg), and just before deployment of the closure de-
vice intravenous heparin is also administrated to achieve 
an activated clotting time > 250 seconds. The most 
frequent vascular access to this procedure is the right 
femoral vein. Then trans-septal puncture is performed 
at the inferoposterior region of the interatrial septum. 
Subsequently the operator has to measure the widest 
anatomic orifice and the depth of LAA, then the closure 
device is implanted according to the manufacturer’s 
recommendation [1]. Device size is based on the widest 
landing zone dimensions [23]. The Watchman device is 
available in sizes from 21 to 33 mm, and it consists of 
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Figure 4. AMPLATZER™ CARDIAC PLUG (adapted from 
the official website of St Jude Medical) [66]
a nitinol frame with a microporous fabric cover [28]. On 
the day of procedure or the day after and on the day of 
discharge a transthoracic echocardiogram (TTE) is ob-
tained [1, 23]. After the procedure patients are on a daily 
dose of aspirin 100 mg and should continue anticoag-
ulation treatment for at least 45 days [using VKAs with 
heparin bridging until the international normalised ratio 
(INR) is in the therapeutic range 2–3] [28]. A scheduled 
TEE is performed 45 days after the procedure, to assess 
the position of the device and the presence of peridevice 
residual flow, and the patients with jet width less than 
5 mm are allowed to discontinue OAT. These patients are 
recommended to take dual antiplatelet therapy (DAPT) 
(aspirin and clopidogrel) for six months, until the follow 
up visit. If a TEE during this visit does not confirm the 
presence of device-related thrombus, monotherapy with 
aspirin is recommended lifelong [28].
Results from studies with Amplatzer 
Cardiac Plug
The largest study using the ACP (St Jude Medical) 
for LAAC conducted by Tzikas (Left atrial appendage 
occlusion for stroke prevention in atrial fibrillation: 
multi-centre experience with the AMPLATZER Cardiac 
Plug) has shown a high procedural success rate and 
favourable outcomes for prevention of AF-related throm-
boembolism [29]. It was a multi-centre, prospective 
study that included data from 1047 patients with AF, who 
underwent LAAC with ACP between 2008 and 2013 at 
22 centres. Clinical 13-month follow-up was completed 
in 98.2% of the patients. The aim of the study was to 
assess the safety, feasibility, and efficacy of LAAC with 
the ACP in a real-world patient population with AF. The 
indications for LAAC were: previous major bleeding 
(47% of patients), high risk of bleeding (35% of patients), 
and coronary stenting mandating triple therapy (22% 
of patients). In 16% of cases one of the indications was 
a stroke on VKAs. Tzikas reported a 97.3% procedural 
success rate [29]. 
Periprocedural serious adverse events (SAEs) 
occurred in 4.97% of the patients. There were 0.8% 
procedure-related deaths, 0.9% strokes, 0.4% transient 
ischaemic attacks (TIA), 1.2% cardiac tamponades, 
and 1.2% of major bleedings. During the 13-month of 
follow-up there were nine strokes (0.9%), and 0.9% of 
TIA, one-year all-cause mortality was reported as 4.2%, 
and none of the deaths was reported as related with 
the LAAC procedure. A peri-device leak was found in 
11.6% of the patients, on average seven months after 
procedure. The annually rate of systemic thromboem-
bolism and major bleeding events was, respectively, 
2.3% and 2.1%. What is interesting, Tzikas reported 
for LAAC a 59% annual reduction rate for prevention 
of AF-related thromboembolism as compared to the 
rate predicted by the CHA2DS2-VASc score and a 61% 
annual reduction in major bleeding events as compared 
to the rate predicted by the HAS-BLED score [29].
Urena and others have designed a trial (Percutane-
ous left atrial appendage closure with the AMPLATZER 
cardiac plug device in patients with nonvalvular atrial 
fibrillation and contraindications to anticoagulation ther-
apy) to assess efficacy and safety of LAAC with ACP in 
patients with nonvalvular AF and absolute contraindica-
tions to OAT [the most common are, respectively, intra-
cranial haemorrhage (34.6%), gastrointestinal bleeding 
(23.1%) or spontaneous haematoma of abdominal 
Figure 3. AMPLATZER™ AMULET™ LEFT ATRIAL 
APPENDAGE OCCLUDER (adapted from the official website 
of St Jude Medical) [66]
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muscles (13.5%)] [30]. A total of 52 patients at mean 
age 74.8 years, who underwent LAAC with ACP, were 
enrolled to this study in seven Canadian centres. The 
mean time of follow-up was 20 ± 5 months. All the 
patients were followed-up at least for 12 months. The 
mean CHADS2 score was 3.
 After the procedure pa-
tients received DAPT for 1–3 months and then single 
antiplatelet therapy (APT). A TEE was performed at the 
six-month follow-up in 74% of patients. Urena reported 
procedural a success rate of 98.1%. The main compli-
cations were: device embolisation (1.9% of patients) 
and pericardial effusion (1.9% of patients). There were 
no cases of periprocedural stroke. Peridevice leak was 
observed in 16.2% of patients at the six-month follow-up 
(as evaluated by TEE). There were no cases of device 
thrombosis [30]. 
During clinical follow-up the rate of death was 5.8%. 
The rates of stroke and systemic embolism were 1.9% 
and 0%, respectively. The rate of major bleeding was 
1.9%, and the rate of pericardial effusion was also 1.9%. 
Summarising, in patients with nonvalvular AF and ab-
solute contraindications to anticoagulation, LAAC with 
ACP followed by DAPT and then APT was associated 
with a low rate of embolic and bleeding events after 
a mean follow-up of 20 months [30]. 
Left atrial appendage closure with Amplatzer 
Cardiac Plug for stroke prevention in atrial fibrillation: 
Initial Asia-Pacific experience (ACP) is a register, 
which assessed initial safety, efficacy, and one-year 
clinical outcomes after LAAC [31]. In 20 patients (age 
68 ± 9 years) with non valvular AF with high risk of 
thromboembolic event (CHADS2 score 2.3 ± 1.3) such 
as with contraindications to OAT, the LAAC procedure 
was successfully performed in 95% of patients, and 5% 
of procedures were stopped due to catheter-related 
thrombus. There were 10% more periprocedural com-
plications, including TEE-related oesophageal injury 
(5%) and coronary artery air embolism (5%). During the 
follow up (12.7 ± 3.1 months) there was no reported 
death, stroke, or device-related thrombus [31].
However, there is no randomised trial in which the 
safety and efficacy of ACP were assessed [31].
Results of studies with the Watchman 
Left Atrial Appendage System
The first randomised study evaluating the efficacy 
and safety of LAAC with a Watchman device was the 
Watchman Left Atrial Appendage Closure (LAAC) Device 
for Embolic PROTECTion in Patients with Atrial Fibrilla-
tion (PROTECT AF) trial. This study demonstrated the 
superiority of the Watchman LAAC system compared to 
warfarin for the combined end point of stroke, systemic 
embolism, and cardiovascular death after 3.8 years of 
follow-up [28, 31–40]. This method, dedicated to pa-
tients with the highest risk of bleeding complications, 
has proven to be even more effective than VKAs in this 
group of patients. It was a multi-centre, randomised 
(2:1 allocation to either Watchman device implantation 
or warfarin therapy), unblinded, Bayesian-designed 
study conducted at 59 hospitals [32]. A total of 707 pa-
tients with nonvalvular AF and at least one additional 
stroke risk factor (CHADS2 score ≥ 1) were enrolled into 
the study [28, 32, 41]. In total 485 patients underwent 
device implantation in this trial [31, 32]. 
The major inclusion criteria to this study were: age 
18 years or older; paroxysmal, persistent, or permanent 
nonvalvular AF; CHADS2 risk score (age ≥ 75 years, 
hypertension, diabetes, heart failure or left ventricular 
systolic dysfunction, prior transient ischaemic attack 
or stroke) result equal to 1 or more points; and contra-
indications to long-term anticoagulation with warfarin 
[32, 41]. Whereas major exclusion criteria were: an 
atrial septal defect, permeable foramen ovale with 
atrial septal aneurysm, mechanical valve prosthesis, 
left ventricular ejection fraction (LVEF) less than 30%, 
mobile aortic atheroma, and symptomatic carotid dis-
ease. A composite efficacy end point included: stroke, 
systemic embolism, and cardiovascular/unexplained 
death. The primary composite safety end point included: 
major bleeding events (intracranial or bleeding requiring 
transfusion) and procedure-related events in the device 
group (pericardial effusion requiring intervention or 
prolonged hospitalisation, procedure-related stroke, 
or device embolisation) [32, 41]. 
The treatment schedule was the same as previous-
ly described. All of these patients underwent TEE at 
five time points: baseline, intraprocedurally, 45 days, 
6 months, and 12 months after implantation [28, 32]. 
TEE was performed at 45 days to assess device position 
and peridevice flow [32, 41]. In patients with jet width 
less than 5 mm, oral anticoagulation with warfarin was 
discontinued and replaced by DAPT (aspirin 81 to 
325 mg and clopidogrel 75 mg) until the six-month 
follow up visit [32, 41]. If there was no thrombus on the 
device in TEE repeated six months after the procedure 
clopidogrel was discontinued and aspirin was recom-
mended life-long [28, 32]. 
After the first year, follow-up visits occurred twice 
yearly, with neurological assessments at 12 months, and 
annually thereafter or whenever a neurological event 
was suspected [32, 41]. The mean CHADS2 scores 
among patients in the warfarin group and the device 
group were 2.3 points and 2.2 points, respectively. 
Approximately two-fifths of the patients had paroxysmal 
AF, and in most cases, this arrhythmia was present 
for one year or longer. This analysis reflects a mean 
(SD) follow up of 3.8 (1.7) years (range, 0–6.5 years). 
Successful implantation of a Watchman device was 
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reported in 88% of patients [32, 41, 42]. After the 45-day, 
6-month, and 12-month TEE estimation warfarin was 
discontinued for 86.8%, 92.2%, and 93.2% of patients, 
respectively [32, 41]. There were 8.4% of primary effica-
cy events in the LAAC group and 13.9% in the warfarin 
patients. The rates of all strokes (5.6% in device group 
vs. 8.2% in the warfarin group) and ischaemic stroke 
(5.2% in device patients vs. 4.1% warfarin patients) did 
not differ significantly between both groups [41]. More 
haemorrhagic strokes occurred in the warfarin group 
(4.0% of patients) than in the device group (0.6% of pa-
tients). In the post-procedural analysis there were 1.3% 
of procedure-related strokes in the device group, which 
was probably caused by technical complications of the 
device implantation, suggesting that stroke prevention 
after LAAC occurs over time. There were deaths from any 
cause: in the warfarin group 18.0%, and 12.3% in the 
device group (p = 0.04).  Moreover, more cardiovascular 
deaths occurred in the warfarin group (9.0%) than in the 
device group (3.7%) [32, 41]. 
What made this new method so promising was a re-
duction in the number of haemorrhagic stroke-related 
deaths in the device group (0.4%) compared with the 
warfarin group (3.3%, p=0.004) [41]. Nevertheless, 
we have to take into account that LAAC is associated 
with early post procedure complications, such as 
periprocedural events, as well as complications related 
to OAT after the procedure. The long-term (3.8 years) 
follow-up of patients randomised in the PROTECT AF 
trial showed that in patients with nonvalvular AF, LAAC 
with Watchman device reduced the relative risk of the 
composite endpoint of cardiovascular death, systemic 
embolism, and stroke by 40% (1.5% absolute reduction) 
compared with anticoagulation with warfarin [41]. Long-
-term follow-up confirmed that there was a decrease in 
the relative risk of all-cause mortality, in favour of the 
strategy based on the Watchman LAA system (34% 
relative reduction, 5.7% absolute reduction). The all-
cause mortality rate in the group treated with warfarin 
was 21.5% compared with 14.5% in the Watchman LAA 
system group for an absolute reduction at five years of 
7.0%. The rate of ischaemic stroke in the Watchman 
LAA system group (1.4%/year) was not significantly 
higher than in the warfarin treated patients (1.1%/year, 
p = 0.49). Of interest, there was no significant difference 
in composite safety outcome between groups [41]. Peri-
cardial effusion with tamponade was frequent (2%), but 
what is more important, it was not a lethal complication 
[41, 43–45]. Procedure-related strokes were probably 
due to embolism of thrombus or air during device im-
plantation procedure. 
After nearly four years of follow-up, the investigators 
demonstrated that percutaneous LAAC met criteria for 
both non-inferiority and superiority, compared with war-
farin therapy, for preventing the combined outcome of 
cardiovascular death, stroke, and systemic embolism, 
as well as superiority for all-cause and cardiovascular 
mortality [41]. Summarising, when we analyse the risk 
of death, intracranial haemorrhage, all strokes, major 
bleeding, and pericardial tamponade, we found clinical 
benefit from LAAC with Watchman device compared to 
warfarin in thromboembolic prophylaxis in patients with 
nonvalvular AF [41, 46].
As we know well, the PROTECT AF trial has several 
limitations: first of all, there were no patients enrolled 
to this trial with absolute contraindications to warfarin 
(because of mandatory post-procedural transition anti-
coagulant therapy with warfarin). Second, there were no 
data comparing the safety and efficacy of the DAnon-
VKAs versus LAAC with Watchman device. Third, one of 
the exclusion criteria was LVEF less than 30%, which is 
a huge study limitation, because unlike anticoagulants, 
LAAC would not prevent thromboembolism from the left 
ventricle. In this trial, patients and physicians were not 
blinded to treatment assignment, because of the study 
design. According to the PROTECT-AF results, health 
care professionals emphasised that the Watchman 
system is an alternative therapeutic strategy, involving 
not just a procedure of device implantation, but more-
over six months of anticoagulation or antithrombotic 
pharmaceutical intervention (or both) because of that, 
this trial does not address patients with absolute contra-
indications to warfarin, who are incapable of transition 
to OAT [41].
CAP (Continued Access Protocol) is a continua-
tion of the observations performed in the PROTECT 
AF trial. The aim of the study was the assessment of 
periprocedural complications regarding the experience 
of the operator in performing the LAAC procedure. 
This register included patients in the PROTECT AF 
trial, who underwent LAAC (542 patients) and those 
from a following nonrandomised registry of patients 
undergoing Watchman implantation (Continued Ac-
cess Protocol [CAP] Registry; 460 patients) [47]. The 
safety endpoints were procedure-related events (device 
embolisation, stroke, and pericardial effusion) and 
bleeding complications. There was a significant decline 
in the rate of procedure- or device-related safety events 
within seven days after the procedure comparing the 
PROTECT-AF Trial and CAP: respectively, 7.7% and 
3.7% of patients (p = 0.007). The rate of pericardial 
effusion within a week after LAAC was lower in the 
CAP Registry (2.2% vs. 5.0% in the PROTECT-AF Trial; 
p = 0.019). However, in the case of procedure-related 
stroke, the results between these two trials were similar 
(0.9% in PROTECT-AF trial versus 0% in CAP Registry; 
p = 0.039) [47].
PREVAIL (Prospective Randomised Evaluation of 
the Watchman Left Atrial Appendage Closure Device in 
Patients With Atrial Fibrillation Versus Long-Term Warfarin 
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Therapy) is an another randomised trial that assessed 
the efficacy and safety of the LAAC. The aim of study 
was to assess the safety and efficacy of LAAC for stroke 
prevention in patients with nonvalvular AF compared 
with long-term warfarin therapy. Patients were randomly 
assigned (2:1) to undergo LAAC (269) or receive chronic 
warfarin therapy (138) [48]. 
The inclusion criteria were a CHADS2 score of one 
point if they also had any of the higher-risk character-
istics: female age ≥ 75 years, ejection fraction ≥ 30% 
but < 35%, age 65 to 74 years and either: diabetes or 
coronary disease, and age ≥ 65 years with congestive 
heart failure. Whereas exclusion criteria were as fol-
lows: contraindication to aspirin or warfarin, indication 
for long-term OAT other than AF, previous stroke/tran-
sient ischaemic attack within 90 days of enrolment, 
symptomatic carotid disease, or a patent foramen 
ovale or atrial septal defect requiring treatment. The 
coprimary efficacy endpoints were: stroke, systemic 
embolism, and cardiovascular/unexplained death, 
whereas the second coprimary efficacy endpoint was 
a composite of stroke or systemic embolism excluding 
the week after randomisation. The third coprimary 
endpoint was early safety, which consisted of all-
cause death, iscahemic stroke, systemic embolism, 
or device-/procedure-related events (requiring open 
cardiovascular surgery or major endovascular inter-
vention between randomisation, and within the first 
week after the procedure). The results of the study 
were reported after 18 months from randomisation, 
and the rate of the first coprimary efficacy endpoint 
was 0.064 in the device group compared with 0.063 in 
the control group and did not achieve the criteria of 
non-inferiority. The rate for the second coprimary 
endpoint was 0.0253 vs. 0.0200, which achieved the 
criteria of non-inferiority. Whereas the second copri-
mary endpoint occurred in 2.2% of the Watchman arm, 
significantly lower than in PROTECT AF. Summarising, 
LAAC was non-inferior to warfarin for ischaemic stroke 
prevention or systemic embolism (excluding a week 
after procedure). However, non-inferiority was not 
achieved for overall efficacy, and event rates were 
comparable in both groups [48].
The EVOLUTION of thromboembolism 
prophylaxis in patients with nonvalvular AF, 
the EWOLUTION Registry
The EWOLUTION registry is an observational, 
prospective, single-arm, multi-centre study, which 
was designed to collect real-world outcome data. In 
this study, the authors collected preoperative and 
operative data of patients who received a Watchman 
LAAC system and had been treated according to the 
standard medical practice of the investigational medical 
centres. Approximately 1000 patients were enrolled at 
up to 70 medical centres in Europe, Russia, and in the 
Middle East, and they were followed for two years. In 
this trial the following endpoints were assessed: Watch-
man implant procedure (successes and complications), 
bleeding events, incidence of stroke and TIA, other 
thromboembolic events, and death [48].
The inclusion criteria into the EWOLUTION Registry 
were: patient eligible for a LAAC with Watchman device 
according to current guidelines; patient willing and 
capable of providing informed consent; age 18 years 
or older. The major exclusion criteria were: patient cur-
rently enrolled in another registry or study (exception: 
participating in a mandatory governmental registry, 
or an observational registry with no associated treat-
ment); woman who is potential childbearing, or plans 
on becoming pregnant; patient is unable or not willing 
to complete follow up visits and examinations. The first 
post-procedure visit is performed 1–3 months after 
the LAAC with Watchman device. During the visit TEE 
or computed tomography (CT) scan is performed to 
assess residual flow around the device, and to confirm 
the absence of thrombus prior to discontinuing OAT 
(VKAs or similar therapies). Follow-up office visits are 
recommended once a year throughout the first two 
years. Enrolment for the EWOLUTION Registry started 
in the autumn of 2013, and the study is expected to be 
completed in the autumn of 2017 [48]. 
Preliminary analyses of this trial are intended to 
focus on three endpoints: procedural success, com-
plications related to the procedure, and incidence of 
stroke or TIA. Specified covariates may affect these 
endpoints, which is why the following variables were 
assessed: gender, age (age of 80 years or more), 
AF pattern, history of major bleeding, TIA, or stroke; 
HAS BLED score (3 points or more), CHADS2 score 
(3 points or more), CHA2DS2-VASc score (5 points or 
more), therapy after implantation (warfarin, DAnonVKAs, 
or antiplatelet drugs), and the presence of multiple 
procedures (compared with Watchman implantation 
procedure alone) [48]. About 60% of the patients 
enrolled to the trial were male, and the mean age was 
73 years [49]. Nearly half of the patients had a history 
of either ischaemic stroke (19.7% of patients), hae-
morrhagic stroke (15% of patients), or TIA (10.7% of 
patients). All the patients enrolled to this trial were at 
high risk of thromboembolic complications-based on 
the CHADS2 and CHA2DS2-VASc risk scores, with an 
average CHADS2 score of 2.8+1.3 and CHA2DS2-VASc 
score of 4.5+1.6. Nevertheless, more than half of the 
patients (62%) were deemed ineligible for OAT, due to 
such factors as bleeding history, high bleeding risk, 
inability to monitor OAT, or co-morbidities. Patients were 
at moderate-to-high risk of bleeding (40% of subjects 
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had a high risk of bleeding with a HAS-BLED score 
of 3 or more), and the average HAS-BLED score was 
2.3+1.2, but what is even more important - almost one-
third of patients had a history of major bleeding (31.2%) 
[49]. Because of the above-mentioned contraindica-
tions, at baseline only 31% of patients were on OAT [50]. 
Other patients enrolled to this registry were on DAPT 
(21% of patients) or on APT (22% of patients), and 27% 
of them were not taking any form of anticoagulant [49]. 
After LAAC with Watchman device implantation, anti-
coagulation was used in line with Watchman device 
recommendations for the first 3–6 months. However, 
the important finding of this register is the fact that 
after Watchman implantation only 27% of patients 
were on OAT, 59% of subjects were on DAPT, and 7% 
were on APT, whereas 6% of them were without any 
type of antiplatelet therapy. A total of 1019 patients 
underwent LAAC procedure with Watchman device, 
with the success rate 98.5%. When we compared the 
preliminary data from the EWOLUTION trial with that 
previously reported from earlier studies, we noticed that 
the rate of successful implantations was higher [PRO-
TECT-AF 90.9%, and CAP (94.4%), PREVAIL (95.1%), 
CAP 2 94.8%]. The two most common reasons for 
the deployment failures were: mismatch between the 
LAA dimensions and the size of Watchman device or 
unfavourable anatomy of LAA. In 99.3% of implanted 
patients the procedure of LAAC was successful because 
there was no or minimal residual flow around the device 
(defined as 5 mm measured in periprocedural TEE). 
SAEs related to procedure and/or device occurred at 
a rate of 2.8% within the first week after implantation, 
and it was lower than in any of the previous Watchman 
LAAC studies (PROTECT-AF 8.7%, CAP 4.1%, PREVAIL 
4.2%). Within the first 24 hours after procedure, 28.5% 
patients experienced SAEs, and 81% of them seem 
to be related to the LAAC procedure [major bleeding, 
pericardial effusion (leading to one tamponade), vascu-
lar damage to the groin, periprocedural air embolism, 
device embolisation, and reinterventions because of 
incomplete LAA seal] [49]. 
Within the first week after procedure, there were 
three deaths, but none of them reported as associated 
with the LAAC procedure. There were four additional 
deaths within the first month, which resulted in 0.7% 
mortality rate within the first month (one of them was 
reported to be associated with the procedure — air 
embolism on the day of the procedure). Within the first 
month, the SAE rate was 7.9%, with an SAE rate of 3.6% 
reported as associated with procedure and/or device. 
The most common SAE was major bleeding requiring 
transfusion, both related to groin access (pseudoaneu-
rysms, laceration of veins), and due to gastrointestinal 
bleeding. In these patients, who suffered from major 
bleeding (with HAS-BLED score ranged from 1 to 5) OAT 
was used in 18% of patients, APT in 29% of patients, 
and DAPT in 41% of patients, whereas 12 % of patients 
were not treated with any form of anticoagulation. There 
were three patients with an ischaemic stroke, none of 
them resulting in death, and two of them with complete 
recovery. In these three patients, two were on DAPT 
(CHADS2 scores were 2 and 3; CHA2DS2-VASc scores 
were 3 and 5), while one patient with very high risk 
(CHADS2 score was 5; CHA2DS2-VASc score was 8) 
was on clopidogrel alone. One case of stroke was 
reported as procedure related [49]. 
Summarising, the incidence of SAEs (related or 
not to the procedure) did not appear to be associated 
with CHADS2 or CHA2DS2-VASc scores, and there 
were no significant differences in incidence of SAEs 
between patients on OAT after LAAC with Watchman 
device compared with patients not on OAT after im-
plantation (p = 0.39). What is more, the incidence of 
SAEs throughout the first month was significantly lower 
in patients ineligible for OAT compared with patients 
eligible for OAT (6.5 vs. 10.2%, p = 0.042). In patients 
with HAS-BLED score less than 3 compared with those 
with score 3 or more, the incidence of SAEs throughout 
first month showed a trend towards higher event rates 
with a higher risk (6.6 vs. 9.9%, respectively, p = 0.078). 
As expected, bleeding complications occurred more 
often in patients with a HAS BLED score 3 or more 
compared with the patients with lower HAS BLED score 
result (1.7 vs. 4.0%, p = 0.029). Comparing to previous 
studies, the EWOLUTION registry suggests a relation-
ship between the number of implants and parameters 
such as successful implantation and complete LAA 
seal. Nevertheless, there was no significant correlation 
between number of implantations and periprocedural 
SAEs (p = 0.33 at 30 days and p = 0.12 at 7 days) [49].
The EWOLUTION registry shows that LAAC can be 
successfully and safely performed in an wide group of 
patients, including those with the highest risk of stroke. 
The average CHADS2 score of 2.8 and CHA2DS2-VASc 
score of 4.5 in the EWOLUTION registry were higher 
compared with patients enrolled to either the PROTECT 
AF (average CHADS2 of 2.2 and CHA2DS2-VASc of 3.4) 
or PREVAIL (CHADS2 score of 2.6 and CHA2DS2-VASc 
of 4.0) trials [50]. Whereas, according to bleeding risk, 
40% of the EWOLUTION population had a HAS BLED 
score 3 or more, compared with 30% of PREVAIL pa-
tients, and only 20% of PROTECT AF subjects [35, 50]. 
Regarding SAEs: the rate of SAEs within the first seven 
days in the EWOLUTION registry was lower than in any 
of the previous Watchman LAAC studies (PROTECT-AF 
8.7%, CAP 4.1%, PREVAIL 4.2%) [35, 50]. Generally, 
the 30-day procedure- or device-related SAE rate was 
assessed as 3.6% [50]. The rate of procedural/de-
vice-related strokes was assessed as 0.1% through the 
first month in this registry, compared with 0.9% in the 
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PROTECT AF and 0.4% in PREVAIL study [48, 50–53]. 
This result might simply be due to less intense use of 
anticoagulation in VKA-ineligible patients [50]. There 
is a theory that some events such as groin bleeding or 
pericardial effusion, have increased likelihood because 
of OAT use, although it was not statistically different 
due to the low event rate. The limitations of the analy-
sis performed in the EWOLUTION registry include: the 
observational nature of the design and the relatively 
short follow-up of 30 days [50].
Until now the randomised trials collected data of 
patients qualified to LAAC with Watchman device, who 
continued VKA for at least 45 days after procedure [50, 
52, 53]. Before the publication of first results of the 
EWOLUTION registry, we had a small number of data 
regarding patients with absolute contraindications to 
oral anticoagulation (only from small registries) [53–55]. 
Nevertheless, the most important fact is that the EWO-
LUTION registry, which includes the patients with and 
without an absolute contraindication to anticoagulation, 
gave us data to assess the benefits and the risk carried 
by the LAAC with Watchman device in these two distinct 
groups of patients [50]. Furthermore, this registry can 
become a basis to plan other studies regarding optimi-
sation of post-procedural pharmacological therapy. To 
the EWOLUTION registry were enrolled over 600 patients 
deemed to be ineligible for OAT, and 738 patients who 
were not prescribed OAT following the procedure [50]. 
The various post-implantation strategies of therapy with 
VKAs, DAnonVKAs, or heparin-derivatives (different drugs 
are used because of, for example, the patient’s contra-
indications), and antiplatelet therapy will be assessed 
to establish optimal management of anticoagulation in 
a population of the patients with a high bleeding risk [49]. 
The ASAP Study (ASA Plavix Feasibility Study With 
Watchman Left Atrial Appendage Closure Technology) 
was a non-randomised trial assessing the safety and effi-
cacy of LAAC in patients with nonvalvular AF ineligible for 
warfarin therapy. In this trial, after LAAC with Watchman, 
patients were administered a thienopyridine antiplatelet 
agent (clopidogrel or ticlopidine) for six months and 
lifelong aspirin. This registry has demonstrated that the 
Watchman device implantation is safe without a warfarin 
transition. Presumably in the future, also thanks to this 
registry, several post-implantation options of anticoag-
ulant or antiplatelet therapy in the early period after the 
procedure, when sealing and re-endothelialisation take 
place, will be used [56].
Left atrial appendage closure vs. the 
new oral anticoagulant drugs
We already know that the Watchman LAAC system 
is non-inferior compared to warfarin for the combined 
endpoint including stroke, systemic embolism, and 
cardiovascular death, but now we would like to answer 
the question: what about DAnonVKAs [28, 31–34]? 
Koifman et al. performed a meta-analysis to compare 
the safety and efficacy of DAnonVKAs versus the LAAC 
with Watchman device in patients with nonvalvular AF, 
in terms of haemorrhagic complications, stroke pre-
ventions, and all-cause mortality [55]. Trials that were 
included to this meta-analysis compared the Watch-
man device with warfarin therapy and DAnonVKAs in 
patients with nonvalvular AF (14 studies of 246,005 pa-
tients: 124,823 treated with warfarin, 120,450 treated 
with DAnonVKAs, and 732 patients had a Watchman 
LAAC system implanted) [11, 15–17, 55, 57–64]. There 
were 12 trials (five of them were RCTs) including 
244,891 patients and comparing DAnonVKAs with war-
farin. There were also two studies (both RCTs) including 
1114 patients in which the Watchman LAAC system 
was compared with warfarin therapy. The mean age 
of patients included to these trials was 72 ± 9 years; 
53% of them were male; and mean CHADS2 score was 
2.1 ± 1.6 points [55]. The analysis showed that there 
was a trend toward reduction in total stroke in patients 
after LAAC; however, this method did not significantly 
reduce the risk of total stroke compared with therapy 
with warfarin (OR = 0.67) [57]. What is more, there was 
a trend toward increased risk of ischaemic stroke with 
the Watchman LAAC device compared with warfarin 
(OR 1.64), but it was not statistically significant [55]. 
As we already know, DAnonVKAs are associated with 
a significant reduction in the total number of strokes 
compared with warfarin (OR = 0.78), even in cases of 
ischaemic stroke (OR 0.63). Regarding major bleeding, 
there was a trend toward a reduction of bleeding events 
after LAAC with Watchman compared with warfarin 
(OR = 0.62). Concluding, both of the new options: 
DAnonVKAs (OR 0.46) and the Watchman LAAC system 
(OR 0.21), significantly decrease the risk of haemor-
rhagic stroke compared with warfarin. Regarding major 
bleeding, these both strategies were comparable, and 
there was no difference between DAnonVKAs com-
pared with the Watchman device (OR 1.25). Now the 
question arises: what is better in this battle? What is 
surprising, this meta-analysis showed that the LAAC 
with Watchman did not significantly reduce the risk 
of haemorrhagic stroke compared with DAnonVKAs 
(OR 0.44, 95% CI 0.09–2.14) [55]. When we compare 
all-cause mortality, there was a trend toward reduction 
for DAnonVKAs (OR = 0.66) and even a weaker trend 
for Watchman device (OR = 0.79) compared with war-
farin [48]. DAnonVKAs led to a significant reduction in 
all-cause mortality (OR 0.89), significant reduction in 
haemorrhagic stroke (OR 0.45), and a trend towards 
reduction in total stroke (OR 0.84) and major bleeding 
(OR 0.79) vs. warfarin, when limiting the included 
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studies to RCTs only. LAAC Watchman device, com-
pared with warfarin, led to a significant reduction in 
haemorrhagic stroke (OR 0.19) and a trend towards 
reduction in all-cause mortality (OR 0.68). Koifman et 
al. emphasised that, when we limit the included trials 
into to RCTs, there was again no significant difference 
between DAnonVKAs and Watchman device in regard 
to any outcome [55].
Conclusions
In recent years significant progress has been made 
in the treatment of patients with nonvalvular AF, espe-
cially in cases with high bleeding risk. This progress 
is associated primarily with the introduction of new 
methods, including LAAC and NOAC drugs, which aim 
at preventing thromboembolic events. In particular, 
LAAC has proven to be effective in a preventive role 
and is also relatively safe. Thus, by providing improved 
capabilities, LAAC significantly enhances a traditional 
suite of antithrombotic treatment procedures that have 
been based mainly on warfarin. 
One of the most difficult challenges of traditional 
drug-based therapies has been the necessity to eval-
uate the balance between the risk of thrombotic and 
haemorrhagic complications. At present LAAC is known 
to provide a superior choice of treatment in patients with 
AF and thromboembolic risk in a few situations such 
as absolute contraindication of systemic OAT, refusal 
by a patient of systemic OAT, and as a complementary 
treatment to anticoagulation in patients with embolic 
events despite adequate OAT. In addition, as a result of 
individual risk/benefit evaluation for OAT vs. alternative 
methods of treatment, LAAC should be considered as 
a therapeutic option for patients with high thromboem-
bolic risk and very high bleeding risk. 
In general, LAAC treatment becomes more attrac-
tive with increasing thromboembolic risk. One of the 
outstanding challenges that remains to be addressed 
in future studies is the question whether LAAC is actu-
ally the best method for preventing thromboembolism 
for patients with moderate/high thromboembolic risk 
and relatively low bleeding risk. Another challenging 
question is to determine the optimum antithrombotic or 
antiplatelet therapy in patients who underwent LAAC, 
especially in patients with high bleeding risk. 
Finally, there is a need to conduct direct comparative 
studies of LAAC and NOAC-based methods of treat-
ment. Notwithstanding the need for future studies and 
further progress, recent advancements associated with 
the introduction of LAAC and NOAC-based methods 
provide today’s health care professional with an un-
paralleled suite of potential therapies that considerably 
improve the outcome of patients with AF.
References
1. Meier B, Blaauw Y, Khattab A et al. EHRA/EAPCI expert consensus 
statement on catheter-based left atrial appendage occlusion. EuroIn-
tervention 2014; 10. DOI: http: //dx.doi.org/10.1093/europace/euu174 
euu174. 
2. Zoni-Berisso M, Lercari F, Carazza T. Epidemiology of atrial fibrillation: 
European perspective. Clinical Epidemiology 2014; 6: 213–220. doi: 
10.2147/CLEP.S47385. 
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of an-
tithombotic therapy in atrial fibrillation. Analysis of pooled data from five 
randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457.
4. DiMarco JP, Flaker G, Waldo AL et al. Affecting bleeding risk during 
anticoagulant therapy in patients with atrial fibrillation: observations 
from the Atrial Fibrillation Follow-up Investigation of Rhythm Manage-
ment (AFFIRM) study. Am Heart J 2005; 149: 650–656.
5. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus VKA in 
patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
6. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus VKA in non-
valvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
7. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus VKA 
in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981–992.
8. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classifi-
cation schemes for predicting stroke: results from the National Registry 
of Atrial Fibrillation. JAMA 2001; 285: 2864B–2870B.
9. Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores 
to aid decision making for thrombophylaxis in nonvalvular atrial fibril-
lation, Circulation 2012; 126: 860–865.
10. Birman-Deych K, Radford MJ, Nilasena DS, Gage BF. Use and ef-
fectivenes of warfarin in medicare beneficiaries with atrial fibrillation. 
Stroke 2006; 37: 1070–1074.
11. Connolly SJ, Ezekowitz MD, Yusuf S et.al., RE-LY Steering Comittee 
and Investigators. dabigatran versus warfarin in patients with atrial 
fibrillation. N Engl J Med 2009; 361: 1139–1151.
12. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory 
patients with nonvalvular atrial fibrillation: the Anticoagulation and 
Risk Factors in Atrial Fibrillation (ATRIA) Study. Ann Intern Med 1999; 
131: 927–934.
13. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in 
patients with atrial fibrillation. N Engl J Med 2009; 360: 2066–2078.
14. Douketis JD. Pharmacologic properties of the new oral anticoagulants: 
A clinical-oriented review with a focus on perioperative management. 
Curr Pharm Des 2010; 16: 3436–3441.
15. Patel MR, Mahaffey KW, Garg J et al.; Investigators. Rivaroxaban versus 
warfarin in nonvalvular atrial fibrillation, N Engl J Med 2011; 365: 883–891.
16.  Granger CB, Alexander JH, McMurray JJ et al., ARISTOTLE Commit-
tees and Investigators. Apixaban versus warfarin in patients with atrial 
fibrillation. N Engl J Med 2011; 365: 981–992.
17. Giugliano RP, Ruff CT, Braunwald E et al.; ENGAGE AF-TIMI 48 Inves-
tigators. Edoxaban versus warfarin in patients with atrial fibrillation. 
N Engl J Med 2013; 369: 2093–2104. 
18. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left 
atrial appendage versus warfarin therapy for prevention of stroke in 
patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 
2009; 374: 534–542.
19. Blackshear J, Odell J. Appendage obliteration to reduce stroke in 
cardiac surgical patients with AF. Ann Thorac Surg 1996; 61: 755–759.
20. Fountain RB, Holmes DR, Chandrasekaran K et al. The PROTECT 
AF (Watchman left atrial appendage system for embolic protecion In 
patients with atrial fibrillation) trial. Am Heart J 2006: 151: 956–961.
21. Cruz-Gonzalez I, Martin-Moreiras J, Garcia E. Thrombus formation 
after left atrial appendage exclusion Rusing an Amplatzer cardiac plug 
device. Catheter Cardiovascular Interv 2011; 78: 970–973.
22. Lammers J, Elenbaas T, Meijer A. Thrombus formation on an Am-
platzer closure device after left atrial appendage closure. Eur Heart 
J 2013; 34: 741.
23. Fahmy P, Spencer R, Tsang M et al. Left atrial appendage closure for 
atrial fibrillation is safe and effective after intracranial or intraocular 
hemorrhage. Can J Cardiol 2016; 32: 349–354.
24. Camm AJ, Lip GY, De Caterina S et al. ESC Committee for Practice 
Guidelines (CPG). 2012 Focused update of the ESC guidelines for the 
management of atrial fibrillation: an update of the 2010 ESC guidelines 
for the management of atrial fibrillation: developed with the special 
contribution of the European Heart Rhythm Association. Eur Heart J 
2012; 33: 2719–2747.
25. Meier B, Blaauw Y, Khattab AA et al. EHRA/ EAPCI expert consensus 
statement on catheter-based left atrial appendage occlusion. EuroIn-
tervention 2014; 10: 1109–1125.
Ewa Obońska, Iwona Świątkiewicz, Left atrial appendage closure
67www.journals.viamedica.pl/medical_research_journal
26. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines 
on myocardial revascularization. Eur Heart J 2014; 35: 2541–2619.
27. Meschia JF, Bushnell C, Boden-Albala B et al.; on behalf of the Ameri-
can Heart Association Stroke Council, Council on Cardiovascular and 
Stroke Nursing, Council on Clinical Cardiology, Council on Functional 
Genomics and Translational Biology, and Council on Hypertension. 
Guidelines for the primary prevention of stroke: a statement for health-
care 21 professionals from the American Heart Association/Ameri-
can Stroke Association. Stroke 2014; 45: 3754–3832.
28. Main ML, Fan D, Reddy VY et al. Assessment of Device-Related 
Thrombus and Associated Clinical Outcomes With the Watchman Left 
Atrial Appendage Closure Device for Embolic Protection in Patients 
With Atrial Fibrillation (from the PROTECT-AF Trial).
29. Tzikas A, Shakir S, Gafoor S et al. Left atrial appendage occlusion for 
stroke prevention in atrial fibrillation: multicentre experience with the 
AMPLATZER Cardiac Plug. Eurointervention 2016; 11: 1170–1179. 
30. Urena M, Rodés-Cabau J, Freixa X et al. Percutaneous left atrial ap-
pendage closure with the AMPLATZER cardiac plug device in patients 
with nonvalvular atrial fibrillation and contraindications to anticoagula-
tion therapy. J Am Coll Cardiol 2013; 62: 96–102.
31. Lam YY, Gabriel WKY, Yu CM et al. Left atrial appendage closure with 
Amplatzer cardiac plug for stroke prevention in atrial fibrillation: Initial 
Asia-Pacific experience. DOI: 10.1002/ccd.23136.
32. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left 
atrial appendage versus warfarin therapy for prevention of stroke in 
patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 
2009; 374: e534–e542.
33. Reddy VY, Doshi SK, Sievert H et al; on behalf of the PROTECT AF 
Investigators. Percutaneous left atrial appendage closure for stroke 
prophylaxis in patients with atrial fibrillation: 2.3 year follow-up of the 
PROTECT AF (Watchman Left Atrial Appendage System for Embolic 
Protection in Patient with Atrial Fibrillation) trial. Circulation 2013; 127: 
e720–e729.
34. Reddy VY, Sievert H, Halperin J et al. PROTECT-AF Steering Commit-
tee and Investigators. Percutaneous left atrial appendage closure vs 
warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014; 
312: e1988–e1998.
35. Reddy VY, Holmes D, Doshi SK et al. Safety of percutaneous left atrial 
appendage closure: results from the watchman left atrial appendage 
system for embolic protection in patients with AF (PROTECT AF) 
clinical trial and the continued access registry. Circulation 2011; 123: 
e417–e424.
36. Khumri TM, Thibodeau JB, Main ML. Transesophageal echocardio-
graphic diagnosis of left atrial appendage occluder device infection. 
Eur J Echocardiogr 2008; 9: e565–e566.
37. Cardona L, Ana G, Luisa B et al. Thrombus formation on a left atrial 
appendage closure device. Circulation 2011; 124: e1595–e1596.
38. Gasparini M, Ceriotti C, Bragato R. Huge left atrial thrombus after 
left atrial appendage occlusion with a Watchman device. Eur Heart 
J 2013; 33: 1998.
39. Plicht B, Konorza TF, Kahlert P et al. Risk factors for thrombus formation 
on the Amplatzer cardiac plug after left atrial appendage occlusion. 
JACC Cardiovasc Interv 2013; 6: 606–613.
40. Massarenti L, Yilmaz A. Incomplete endothelialization of left atrial ap-
pendage occlusion device 10 months after implantation. J Cardiovasc 
Electrophysiol 2012; 23: 1384–1385.
41. Reddy VY, Sievert H, Halperin J et al.; for the PROTECT AF Steering 
Committee and Investigators. Percutaneous Left Atrial Appendage 
Closure vs Warfarin for Atrial Fibrillation A Randomized Clinical Trial. 
JAMA 2014; 312: 1988–1998. 
42. Reddy VY, Doshi SK, Sievert H et al; PROTECT AF Investiga-
tors. Percutaneous left atrial appendage closure for stroke pro-
phylaxis in patients with atrial fibrillation: 2.3-year follow-up of the 
PROTECT AF (Watchman Left Atrial Appendage System for Embolic 
Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 
127: 720–729.
43. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of 
anticoagulants on cancer risk and survival: systematic review. Cancer 
Treat Rev 2007; 33: 358–368.
44. Reddy VY, Holmes D, Doshi SK et al. Safety of percutaneous left atrial 
appendage closure: results from the Watchman Left Atrial Appendage 
System for Embolic Protection in Patients with AF (PROTECT AF) 
clinical trial and the Continued Access Registry. Circulation 2011; 
123: 417–424.
45. Calkins H, Brugada J, Packer DL et al; European Heart Rhythm 
Association (EHRA); European Cardiac Arrhythmia Society (ECAS); 
American College of Cardiology (ACC); American Heart Association 
(AHA); Society of Thoracic Surgeons (STS). HRS/EHRA/ECAS expert 
Consensus Statement on catheter and surgical ablation of atrial 
fibrillation: recommendations for personnel, policy, procedures and 
follow-up: a report of the Heart Rhythm Society (HRS) Task Force 
on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 
2007; 4: 816–861.
46. Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left 
atrial appendage closure for stroke prevention in patients with atrial 
fibrillation: an assessment of net clinical benefit. Eur Heart J 2012; 
33: 2700–2708.
47. Reddy VY, Holmes D, Doshi SK et al; Safety of Percutaneous Left 
Atrial Appendage Closure Results From the Watchman Left Atrial 
Appendage System for Embolic Protection in Patients With AF 
(PROTECT AF) Clinical Trial and the Continued Access Registry. 
Interventional Cardiology.
48. Holmes DR Jr, Kar S, Price MJ et al. Prospective randomized evaluation 
of the Watchman left atrial appendage closure device in patients with 
atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. 
J Am Coll Cardiol 2014; 64: 1–12.
49. Boersma LVA, Schmidt B, Betts TR et al. EWOLUTION: Design of 
a Registry to Evaluate Real-World Clinical Outcomes in Patients 
With AF and High Stroke Risk-Treated With the Watchman Left Atrial 
Appendage Closure Technology. Catheter Cardiovasc Interv 2016; 
88: 460–465.
50. Boersma LVA, Schmidt B, Betts TR et al., on behalf of the EWOLUTION 
investigators. Implant success and safety of left atrial appendage 
closure with the Watchman device: peri-procedural outcomes from 
the EWOLUTION registry. Eur Heart J 2016; 37: 2465–2474.
51. Holmes DR Jr, Kar S, Price MJ et al. Prospective randomized evaluation 
of the Watchman Left Atrial Appendage closure device in patients with 
atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. 
J Am Coll Cardiol 2014; 64: 1–12.
52. Chun KR, Bordignon S, Urban V et al. Left atrial appendage closure 
followed by 6 weeks of antithrombotic therapy: A prospective sin-
gle-center experience. Hearth Rhythm 2013; 10: 1792–1799. 
53. Bergmann MW. New technical and anticoagulation aspects for left 
atrial appendage closure using the Watchman device in patients not 
taking VKA. EuroIntervention 2013; 9: 463–468.
54. Reddy VY, Mobius-Winkler S, Miller MA et al. Left atrial appendage 
closure with the Watchman device in patients with a contraindication 
for oral anticoagulation. The ASAP study (ASA Plavix Feasibility Study 
With Watchman Left Atrial Appendage Closure Technology). J Am Coll 
Cardiol 2013; 61: 2551–2556.
55. Koifman E, Lipinski MJ, Ricardo O et al. Comparison of Watchman de-
vice with new oral anti-coagulants in patients with atrial fibrillation: 
A network meta-analysis. MedStar Cardiovascular Research Network, 
MedStar Heart and Vascular Institute, MedStar Washington Hospital 
Center, Washington, DC, USA, journal homepage: www.elsevier 
.com/locate/ijcard.
56. Reddy VY, Möbius-Winkler S, Miller MA et al. Left Atrial Appendage 
Closure With the Watchman Device in Patients With a Contraindication 
for Oral Anticoagulation. J Am Coll Cardiol 2013; 61: 2551–2556. doi: 
10.1016/j.jacc.2013.03.035.
57. Aslan O, Yaylali YT, Yildirim S et al., Dabigatran versus warfarin in atrial 
fibrillation: multicenter experience in Turkey. Clin Appl Thromb Hemost 
2016; 22: 147–152.
58. Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, 
bleeding, and mortality risks in elderly Medicare patients treated with 
dabigatran or warfarin for nonvalvular atrial fibrillation, Circulation 
2015; 131: 157–164.
59. Ho CW, Ho MH, Chan PH et al., Ischemic stroke and intracranial 
hemorrhage with aspirin, dabigatran, and warfarin: impact of quality 
of anticoagulation control. Stroke 2015; 46: 23–30.
60. Ho JC, Chang AM, Yan BM et al. Dabigatran compared with warfarin 
for stroke prevention with atrial fibrillation: experience in Hong Kong, 
Clin Cardiol 212; 35: E40–E45.
61. Hori M, Matsumoto M, Tanahashi N et al., Study investigators. Rivar-
oxaban vs. warfarin in Japanese patients with atrial fibrillation — the 
J-ROCKET AF study. Circ J 2012; 76: 2104–2111.
62. Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral an-
ticoagulants in clinical practice: a report from three centers in Sweden. 
Thromb J 2014; 12: 29.
63. Laliberte F, Cloutier M, Nelson WW et al., Real-world comparative 
effectiveness and safety of rivaroxaban and warfarin in nonvalvular 
atrial fibrillation patients. Curr Med Res Opin 2014; 30: 1317–1325. 
64. Larsen TB, Rasmussen LH, Skjoth F et al., Efficacy and safety of 
dabigatran etexilate and warfarin in “real-world” patients with atrial 
fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 
2013; 61: 2264–2273.
65. The official website of Boston Scientific.
66. The official website of St. Jude Medical.
